Claims for Patent: 9,522,174

Summary for Patent: 9,522,174

Title:	Stable liquid interferon beta formulations
Abstract:	Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
Inventor(s):	DiBiase; Mary D. (Wellesley, MA), Chung; Wen-Li (San Mateo, CA), Staples; Mark (Cambridge, MA), Scharin; Eric (San Mateo, CA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	14/564,637
Patent Claims:	1. A method for preparing an interferon-beta formulation, comprising the step of mixing a liquid composition comprising interferon-beta with a sterile diluent, wherein the liquid composition further comprises a stabilizing agent at between about 0.3% and 5% by weight, wherein the liquid composition has not been previously lyophilized, wherein the formulation does not comprise serum albumin, and wherein the stabilizing agent is either arginine or glycine. 2. The method of claim 1, wherein the formulation has a pH of between about 4.0 and 7.2. 3. The method of claim 1, wherein the formulation has a pH of between about 4.0 and 5.0. 4. The method of claim 1, wherein the formulation has a pH of between about 4.5 and 5.5. 5. The method of claim 1, wherein the formulation has a pH of between about 4.8 and 5.2. 6. The method of claim 1, wherein the arginine is arginine-HCl. 7. The method of claim 1, wherein the interferon-beta is present in the formulation at between 6 MIU/ml and 50 MIU/ml. 8. The method of claim 1, wherein the formulation further comprises a solution of a weak acid comprising acetate and acetate salt. 9. The method of claim 8, wherein the acetate or acetate salt is present at 20 mM. 10. The method of claim 1, wherein the formulation further comprises a surfactant. 11. The method of claim 1, wherein the liquid formulation has a dissolved oxygen level that is less than 30% of atmospheric equilibrium levels. 12. The method of claim 11, wherein the liquid formulation has a dissolved oxygen level that is less than or equal to 10% of atmospheric equilibrium levels. 13. The method of claim 1, wherein the diluent is a buffer having a pH of between about 4.0 and 7.2. 14. The method of claim 1 or 13, wherein the method further comprises the step of filter sterilizing the formulation. 15. The method of claim 1 or 13, wherein the method further comprises the step of transferring the formulation to a sterile syringe.

Details for Patent 9,522,174

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2016-12-24